The Ridgewood Blog Brings a Free Market Laissez-faire Point of View to Local, New Jersey State and National Issues.
the staff of the Ridgewood blog
Ridgewood NJ, while many voters have become skeptical toward the federal government’s response to the COVID-19 pandemic, a majority of Democrats embrace restrictive policies, including punitive measures against those who haven’t gotten the COVID-19 vaccine.
Continue reading COVID-19: Democratic Voters Support Harsh Measures Against Unvaccinated
the staff of the Ridgewood blog
Ridgewood NJ, according to Superintendent of Schools Dr. Gorman , at recent vaccine clinics offered by the Village of Ridgewood Health Department, over 600 people received the COVID-19 vaccine, including students of all ages. The Health Department will be offering additional vaccine clinics soon.
photo of Michinori Kohara
the staff of the Ridgewood blog
Researchers at the Tokyo Metropolitan Institute of Medical Science are working on a COVID-19 vaccine that not only delivers lifelong immunity against the SARS-CoV-2 virus but could also be transported at room temperature to far-off corners of the world, The Japan Times reported.
the staff of the Ridgewood blog
Washington DC, the Occupational Safety and Health Administration (OSHA) is suspending enforcement of the Biden administration’s COVID-19 vaccine mandate for large private businesses after a federal appeals court upheld a stay on it last week.
the staff of the Ridgewood blog
Washington DC, today, the U.S. Food and Drug Administration approved the first COVID-19 vaccine. The vaccine has been known as the Pfizer-BioNTech COVID-19 Vaccine, and will now be marketed as Comirnaty (koe-mir’-na-tee), for the prevention of COVID-19 disease in individuals 16 years of age and older. The vaccine also continues to be available under emergency use authorization (EUA), including for individuals 12 through 15 years of age and for the administration of a third dose in certain immunocompromised individuals.
Continue reading FDA Gives Full Approval to Pfizer’s COVID-19 Vaccine
the staff of the Ridgewood blog
Ridgewood NJ, Distrust of public health officials may be a major factor in people refusing to get the COVID-19 vaccine. Nearly a third of Americans believe officials are lying about vaccine safety, a number that rises to almost two-thirds among those who say they don’t intend to get vaccinated against the coronavirus.
the staff of the Ridgewood blog
the staff of the Ridgewood blog
Ridgewood NJ, Can employers require workers to get vaccinated against the coronavirus? At least one lawsuit has already been filed against such a workplace requirement, and Americans aren’t sure employers should be able to make COVID-19 vaccination mandatory.
Continue reading Majority of Americans Wary of Making COVID-19 Vaccine Mandatory
the staff of the Ridgewood blog
Washington DC, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the third vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The EUA allows the Janssen COVID-19 Vaccine to be distributed in the U.S for use in individuals 18 years of age and older.
the staff of the Ridgewood blog
Hackensack NJ, Hackensack Meridian Health, the largest and most integrated health network in New Jersey, announced today that it has administered its 100,000th COVID-19 vaccine on February 12, 2021. The network reached this major milestone just two months after it launched its vaccination deployment program on December 15, 2020.
the staff of the Ridgewood blog
New Brunswick NJ, Johnson & Johnson (NYSE: JNJ) (the Company) today announced that Janssen Biotech, Inc., has submitted an application to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) for its investigational single-dose Janssen COVID-19 vaccine candidate. The Company’s EUA submission is based on topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, demonstrating that the investigational single-dose vaccine met all primary and key secondary endpoints. The Company expects to have product available to ship immediately following authorization.
the staff of the Ridgewood blog
NEW BRUNSWICK NJ, Johnson & Johnson (NYSE: JNJ) (the Company) today announced topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, demonstrating that the investigational single-dose COVID-19 vaccine in development at its Janssen Pharmaceutical Companies met all primary and key secondary endpoints. The topline safety and efficacy data are based on 43,783 participants accruing 468 symptomatic cases of COVID-19.
the staff of the Ridgewood blog
GAITHERSBURG MD, Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that NVX-CoV2373, its protein-based COVID-19 vaccine candidate, met the primary endpoint, with a vaccine efficacy of 89.3%, in its Phase 3 clinical trial conducted in the United Kingdom (UK). The study assessed efficacy during a period with high transmission and with a new UK variant strain of the virus emerging and circulating widely. It was conducted in partnership with the UK Government’s Vaccines Taskforce. Novavax also announced successful results of its Phase 2b study conducted in South Africa.
Continue reading Novavax COVID-19 Vaccine Demonstrates Near 90% Efficacy in UK Phase 3 Trial
the staff of the Ridgewood blog
Trenton NJ, for those New Jerseyans who have received the first Covid-19 vaccine dose, there’s another wave of confusion about how to get the second dose within the recommended time frame.
Assembly Republican Leader Jon Bramnick is calling for Legislative hearings to fix the problem.
Continue reading NJ Mega Site Fumbles Second Covid-19 vaccine Dose
